• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Publications

Rabe T, Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Mueck A O, Albring C, Thrombophilie und/oder Z. n. Thromboembolie: Auswahl der richtigen Kontrazeption - Teil 2: Vorgehen bei Risikogruppen. . Gyne Fachzeitschrift für den Arzt der Frau. 2012; Jan;32 Jahrgang.
Heinemann Lothar A , Do Minh Thai, Heinemann Klaas, Lindemann M , Filonenko A, Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women International. 2012; Feb;33(2):109-24.
Dinger Jürgen, M Kieble, Rare serious adverse events: comparison of patient- and physician-reported outcomes. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 732. DOI 10.1002.
Dinger Jürgen, Assmann Anita, Oral contraceptives and the risk of VTE: reanalysis of the EURAS/LASS study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 74.
Rabe T, Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Mueck A O, Albring C, Thrombophilie und/oder Z. n. Thromboembolie: Auswahl der richtigen Kontrazeption - Teil 1: Vorgehen bei Risikogruppen. . Gyne Fachzeitschrift für den Arzt der Frau,. 2011; Dec;32 Jahrgang.
Dinger Jürgen, Bardenheuer Kristina, Assmann Anita, Safety and effectiveness of oral contraceptives in obese women. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 15.
Bardenheuer Kristina, Dinger Jürgen, Franke Christian, Impact of obesity on the safety and effectiveness of oral contraceptives. 56. GMDS-Jahrestagung und 6. DGEpi-Jahrestagung, German Medical Science GMS Publishing House. 2011; Doc11gmds331..
Dennerstein L, Lehert P, Heinemann Klaas, Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause International. 2011; Sep: 17(3):96-101. 10.1258/mi.2011.011028.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and the risk of uterine perforation: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 233.
Dennerstein L, Lehert P, Heinemann Klaas, Global study of women's experiences of premenstrual symptoms and their effects on daily life. Menopause International. 2011; Sep: 17(3):88-95. 10.1258/mi.2011.011027.
Dinger Jürgen, Franke Christian, Use of hormonal contraceptives in europe and in the USA: comparative data from the TASC study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 182.
Rabe T, Goeckenjan M, Ahrendt H-J, Crosignani PG, Dinger Jürgen, Mueck A O, Lohr PA, Creinin MD, Sabatini R, Strowitzki T, Oral contraceptive pills: combinations, dosages and the rational behind 50 years of oral hormonal contraceptive development. J Reproduktionsmed Endokrinol. 2011; 8 (Special Issue 1): 33-104.
  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Interim pages omitted …
  • Page 22
  • Go to Next Page »

sidebar

Search our Publications

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2026 ZEG Berlin

Impressum

Website by Laura Yeffeth.